(Q44888557)

7 December 2017

title

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation (English)

1 reference

7 December 2017

Mohty M

1

1 reference

7 December 2017

Boiron JM

2

1 reference

7 December 2017

Damaj G

3

1 reference

7 December 2017

Michallet AS

4

1 reference

7 December 2017

Bay JO

5

1 reference

7 December 2017

Faucher C

6

1 reference

7 December 2017

Perreau V

7

1 reference

7 December 2017

Bilger K

8

1 reference

7 December 2017

Coso D

9

1 reference

7 December 2017

Stoppa AM

10

1 reference

7 December 2017

Tabrizi R

11

1 reference

7 December 2017

Gastaut JA

12

1 reference

7 December 2017

Michallet M

13

1 reference

7 December 2017

Maraninchi D

14

1 reference

7 December 2017

Blaise D

15

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Bone Marrow Transplantation

7 December 2017

published in

1 reference

7 December 2017

volume

34

1 reference

7 December 2017

issue

1

1 reference

7 December 2017

page(s)

77-84

1 reference

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Hematopoietic Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

1 reference

7 January 2021

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Autologous and allogeneic transplantation for multiple myeloma at a single centre

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Recent Developments in Hematopoietic Stem Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Hematopoietic stem cell transplantation for hematological malignancies in Europe.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704531

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704531

1 reference

7 December 2017

1 reference